\
&
Contact us
\
&
Contact us
Published on | 5 years ago
Programmes ERC RI MSCA FET ICT NMBP SPACE Risk Finance SME Instrument Health Food Energy Transport Climate/Environment Societies Security Widening SwafS JRC COST EIC Pilot Batteries Circular Industries Horizon 2020 H2020 L+FThe recent escalation of restrictions related to the COVID-19 outbreak may hamper applicants’ ability to prepare and finalise high-quality proposals. For this reason, for Horizon 2020 calls with original deadlines between now and 15 April, extensions will be applied. The precise new deadlines for each call and topic will be published on the call and topic pages on the Funding and Tenders Portal.
For the following two calls, no extension of deadline/cutoff date will apply:
In all cases, potential applicants are advised to prepare themselves as necessary, especially by establishing effective communication links for remote collaborative work, also anticipating possible further restrictions in the coming weeks.
Source: Funding and tender portal – FAQ
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
